GeLongHui October 23rd | Jiangxi Fushine Pharmaceutical (300497.SZ) released the third quarter report of 2024, with revenue of 0.294 billion yuan, a year-on-year decrease of 31.65%; net income attributable to shareholders of the listed company -39.6157 million yuan; net profit attributable to shareholders of the listed company excluding non-recurring gains and losses -44.7531 million yuan; basic earnings per share -0.07 yuan.
富祥药业(300497.SZ)：第三季度净亏损3961.57万元
Jiangxi Fushine Pharmaceutical (300497.SZ): The net loss in the third quarter was 39.6157 million yuan.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated